Nanobiotix S.A. Stock Price, News & Analysis

Nanobiotix (NASDAQ:NBTX) has released its monthly update on voting rights and share capital as of August 31, 2025. The company reported 48,236,771 shares outstanding, with 50,337,954 theoretical voting rights and 50,315,836 exercisable voting rights.

This disclosure is made in compliance with French regulatory requirements, as the company is listed on both Euronext Paris and Nasdaq.

Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's management team, including CEO Laurent Levy and CFO Bart van Rhijn, will participate in a fireside chat on Tuesday, September 9th, 2025, at 9:00 am EDT. The presentation will be accessible via webcast on the company's investor relations website, with a replay available after the event.

Nanobiotix (NASDAQ: NBTX) has reported its latest voting rights and share capital status as of July 31, 2025. The company disclosed a total of 48,236,671 shares outstanding, with 50,340,736 theoretical voting rights and 50,318,618 exercisable voting rights.

Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, with dual listings on Euronext Paris and Nasdaq Global Select Market. The company specializes in physics-based therapeutic approaches and owns over 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.

Nanobiotix (NASDAQ: NBTX) announced two significant developments for its radioenhancer JNJ-1900 (NBTXR3). First, major European health authorities have reclassified the product from a medical device to a medicinal product, aligning with its status in the US and other major markets. This reclassification follows updated insights into the product's mechanism of action.

Second, the company has filed a new composition of matter patent for JNJ-1900, which is currently licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company. The product is undergoing extensive global clinical development, including a pivotal Phase 3 trial in head and neck cancer, across multiple tumor types and therapeutic combinations.

Nanobiotix (NBTX) has reported its latest voting rights and share capital status as of May 31, 2025. The company disclosed that it has 47,426,851 shares outstanding. The total number of theoretical voting rights stands at 49,529,244, while the exercisable voting rights amount to 49,507,126. This regular update, required by French regulatory authorities, provides transparency regarding the company's capital structure and voting rights distribution. The disclosure complies with the French Commercial Code and the General Regulation of the French Financial Markets Authority (AMF).

Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's Chief Financial & Business Officer, Bart van Rhijn, will participate in a fireside chat on June 5, 2025, at 3:45 PM EDT in New York. The presentation will be accessible via webcast on the company's investor relations website, with a replay available after the event.

Nanobiotix (NBTX) reported key operational and financial updates for Q1 2025. The company achieved significant milestones in its JNJ-1900 (NBTXR3) development programs, including the dosing of the first patient in the CONVERGE Phase 2 study for stage 3 unresectable non-small cell lung cancer. Clinical data presentations at major conferences demonstrated promising results in lung cancer re-irradiation and pancreatic cancer studies.

The company strengthened its financial position through an amendment to the global licensing agreement for JNJ-1900, which extended its cash runway into mid-2026 and reduced operational cash burn. As of March 31, 2025, Nanobiotix reported €39.8 million in cash and cash equivalents. The agreement modification removed most funding obligations for NANORAY-312 while maintaining potential milestone and royalty payments.

Nanobiotix (NBTX) has reported its latest voting rights and share capital status as of April 30, 2025. The company disclosed having 47,426,851 shares outstanding, with 49,535,883 theoretical voting rights and 49,513,765 exercisable voting rights. This regular monthly disclosure is required by French regulatory authorities for companies listed on Euronext Paris.

Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ. The company's Chief Financial & Business Officer, Bart van Rhijn, will participate in a fireside chat on Tuesday, May 20, 2025, at 5:00 pm EDT in New York. The presentation will be webcast live and available for replay on the company's investor relations website.